-
IASLC Looks Back at 50 Years of Growth, Collaboration, and Progress in Lung Cancer
A special plenary at WCLC 2024 recognized a half-century of advances in thoracic oncology while reflecting on how far the IASLC has come since its first meeting.
More News from #WCLC25
-
Test Your Knowledge at the Closing Lunch of the 2025 World Conference on Lung Cancer
Before you depart Barcelona, join your colleagues for lunch and an entertaining trivia competition, hosted by quizmaster Stephen Liu, MD.
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
Dr. David Planchard said the findings support a combination approach as a first-line treatment with an extended overall survival advantage for patients with EGFRm advanced NSCLC.